Cargando…
Efficacy of osimertinib in a patient with non-small cell lung cancer harboring epithelial growth factor receptor exon 19 deletion/T790M mutation, with poor performance status
Osimertinib, a third-generation epithelial growth factor receptor (EGFR) tyrosine kinase inhibitor, has been demonstrated to be effective for treating patients with T790M-positive advanced non-small cell lung cancer (NSCLC) with a relatively good performance status (grade 0–1). Reports of therapeuti...
Autores principales: | Nishii, Yoichi, Hataji, Osamu, Ito, Kentaro, Watanabe, Fumiaki, Kobayashi, Tetsu, D’Alessandro-Gabazza, Corina, Toda, Masaaki, Taguchi, Osamu, Yamamoto, Nobuyuki, Gabazza, Esteban C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5774518/ https://www.ncbi.nlm.nih.gov/pubmed/29399354 http://dx.doi.org/10.3892/mco.2017.1522 |
Ejemplares similares
-
Smart watch-based coaching with tiotropium and olodaterol ameliorates physical activity in patients with chronic obstructive pulmonary disease
por: Hataji, Osamu, et al.
Publicado: (2017) -
Factors leading to failure to diagnose pulmonary malignant tumors using endobronchial ultrasound with guide sheath within the target lesion
por: Nishii, Yoichi, et al.
Publicado: (2019) -
De Novo T790M Mutation in an L858R Epidermal Growth Factor Receptor Mutant-Associated Lung Adenocarcinoma
por: Fujiwara, Takumi, et al.
Publicado: (2020) -
Renal Injury during Long-Term Crizotinib Therapy
por: Yasuma, Taro, et al.
Publicado: (2018) -
Good Response of Advanced Thymic Carcinoma with Low PD-L1 Expression to Chemotherapy plus Pembrolizumab as First-Line Therapy and to Pembrolizumab as Maintenance Therapy: A Case Report
por: Nishii, Yoichi, et al.
Publicado: (2022)